Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.52 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317381 | 0.85 | SIGMAR1 (0.54) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL3318085 | 0.83 | SIGMAR1 (0.49) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL7248849 | 0.75 | CCR3 (0.73) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL7247832 | 0.73 | CCR3 (0.72) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL18691807 | 0.72 | CCR3 (0.56) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL360084 | 0.72 | KCNH2 (0.77) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL14067111 | 0.72 | CCR3 (0.71) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| Bromide SCHEMBL7249670 | 0.72 | CCR3 (0.70) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL29244366 | 0.72 | CCR3 (0.75) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL7403436 | 0.71 | CCR3 (0.75) | CCR3PRMT6CARM1PRMT3PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| EP-2066648-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008015266-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | SIGMAR1, TMEM97, OPRK1 | CCR3 2461/4885PRMT6 2017/4885CARM1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.